Enrique Velasquez, MD
Cardiovascular Disease · Huntsville, ALNPI 1972574051
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $11,438 of the $14,488 with a category attached, or 78.9%. 27 manufacturers reported payments, led by AstraZeneca at 26.9% of the total. Reporting peaked in 2020 at $3,978 and has fallen 63.1% since, to $1,467 in 2025.
Across 582 payments — averaging $24.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$4K
- Novartis$2K
- Boston Scientific$1K
- Johnson & Johnson$1K
- Amgen$1K
- Pfizer$920
- plus $4K from 21 others
Across 155 payments — averaging $708.41 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$41K
- Boehringer Ingelheim International GmbH$39K
- Boehringer Ingelheim Pharma GmbH & Co.kg$30K
What the payments were for
- Speaking & faculty fees$3,05021%
- Food & beverage$11,43879%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 38 | $3,900 |
| Novartis | 113 | $2,062 |
| Boston Scientific | 66 | $1,424 |
| Johnson & Johnson | 72 | $1,054 |
| Amgen | 49 | $1,021 |
| Pfizer | 47 | $920 |
| Boehringer Ingelheim | 31 | $695 |
| E.r. Squibb & Sons, L.L.C. | 25 | $611 |
| Regeneron Healthcare Solutions, Inc. | 21 | $462 |
| Novo Nordisk | 16 | $276 |
| Merck | 12 | $270 |
| Bayer | 13 | $262 |
| Sanofi-aventis U.S. LLC | 14 | $244 |
| Abbott | 5 | $221 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 10 | $189 |
| Gilead | 16 | $181 |
| Esperion Therapeutics, Inc. | 9 | $164 |
| Actelion Pharmaceuticals US, Inc. | 7 | $138 |
| United Therapeutics Corporation | 3 | $99 |
| Otsuka America Pharmaceutical, Inc. | 3 | $71 |
| Heartflow, Inc. | 1 | $47 |
| Siemens Medical Solutions USA, Inc. | 2 | $37 |
| Chiesi USA, Inc. | 3 | $37 |
| Alnylam Pharmaceuticals Inc. | 2 | $34 |
| Scpharmaceuticals Inc. | 2 | $33 |
| Bridgebio Pharma, Inc. | 1 | $19 |
| Endotronix, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$3,300
- WATCHMAN Access System$427
- Repatha$232
- CAMZYOS$125
- MitraClip System$124
- JARDIANCE$110
- RESONATE EL ICD VR$106
- VYNDAQEL$103
How this compares
$14,488 in reported general payments places this provider in the 85th percentile of 292 cardiovascular disease providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 562 | $511,103 |
| EntrestoSacubitril/Valsartan | 255 | $282,168 |
| XareltoRivaroxaban | 151 | $150,596 |
| FarxigaDapagliflozin Propanediol | 66 | $77,525 |
| JardianceEmpagliflozin | 58 | $61,542 |
| Repatha SureclickEvolocumab | 50 | $46,211 |
| Ranolazine ErRanolazine | 101 | $12,863 |
| Metoprolol Succinate | 621 | $11,200 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 19 | $7,336 |
| Atorvastatin Calcium | 438 | $6,002 |
| Flecainide Acetate | 94 | $5,797 |
| Clonidine | 26 | $5,548 |
| Praluent PenAlirocumab | 12 | $5,515 |
| Amiodarone Hcl | 136 | $5,293 |
| Carvedilol | 380 | $3,872 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $920 | $511,103562 claims |
| NovartisEntresto | $2,062 | $282,168255 claims |
| Johnson & JohnsonXarelto | $1,054 | $150,596151 claims |
| AstraZenecaFarxiga | $3,900 | $77,52566 claims |
| Boehringer IngelheimJardiance | $695 | $61,54258 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 292 cardiovascular disease providers in Alabama.
Other cardiovascular disease in Huntsville
- James MurphyHuntsville$18K
- Warren FosterHuntsville$13K
- Warren StricklandHuntsville$11K
- Joshusa ValtosHuntsville$11K
- Sadasiva KattaHuntsville$10K
- Christian DeutschHuntsville$9K
- Dennis ThomasMobile$894K
- David FienoAlabaster$421K
- Vikram AroraBirmingham$271K
- Jason ThompsonBirmingham$248K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.